Alkylating agents and platinum: is clinical resistance simply a tumor cell phenomenon?
- PMID: 1843107
Alkylating agents and platinum: is clinical resistance simply a tumor cell phenomenon?
Abstract
Alkylating agents and platinum compounds comprise a large group of drugs that may exhibit marked differences in pharmacologic properties on the subcellular and clinical levels. Studies of the subcellular pharmacology of individual agents in this group suggest that cellular resistance to these drugs as a class may be modulated at three general levels: transmembrane drug accumulation, cytosolic inactivation of drug, and altered DNA repair. Traditionally, one unspoken assumption of cancer chemotherapy has been that in vitro tumor cell resistance equates with clinical resistance. Recent studies of platinum DNA adduct in nonmalignant tissues from cancer patients actively receiving therapy suggest that this assumption should be reassessed. In studies of platinum-DNA adduct from four different groups (using four different methods to assess adduct levels in nonmalignant tissues), the relationship between adduct level and disease response is a direct one; ie, the higher the adduct level, the better the clinical response to therapy. Here the data are reviewed that suggest that clinical resistance to DNA-damaging agents is not simply a tumor cell phenomenon and may represent the pharmacogenetic ability of individuals to protect cellular DNA.
Similar articles
-
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.Cancer Res. 1997 Mar 1;57(5):850-6. Cancer Res. 1997. PMID: 9041185
-
Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.Clin Cancer Res. 1996 Nov;2(11):1829-35. Clin Cancer Res. 1996. PMID: 9816137 Clinical Trial.
-
Excision repair cross complementing-group 1: gene expression and platinum resistance.Int J Mol Med. 2004 Dec;14(6):959-70. Int J Mol Med. 2004. PMID: 15547660 Review.
-
Clinical reversal of drug resistance in ovarian cancer.Gynecol Oncol. 1993 Oct;51(1):90-6. doi: 10.1006/gyno.1993.1252. Gynecol Oncol. 1993. PMID: 8244181 Review.
-
Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.Cancer Res. 1990 Apr 15;50(8):2256-60. Cancer Res. 1990. PMID: 2180564
Cited by
-
Clinical significance of cellular resistance in tumours to cytotoxic chemotherapy and radiotherapy.Cytotechnology. 1993;12(1-3):385-91. doi: 10.1007/BF00744675. Cytotechnology. 1993. PMID: 7764459 Review.
-
Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer.Evid Based Complement Alternat Med. 2020 Apr 30;2020:7376568. doi: 10.1155/2020/7376568. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32419821 Free PMC article.
-
Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat.J Pain. 2009 May;10(5):534-41. doi: 10.1016/j.jpain.2008.12.003. Epub 2009 Feb 23. J Pain. 2009. PMID: 19231296 Free PMC article.
-
Subcutaneous ω-Conotoxins Alleviate Mechanical Pain in Rodent Models of Acute Peripheral Neuropathy.Mar Drugs. 2021 Feb 11;19(2):106. doi: 10.3390/md19020106. Mar Drugs. 2021. PMID: 33670311 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources